These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 32065848)
1. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity. Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848 [TBL] [Abstract][Full Text] [Related]
2. Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting. Keller AM; Xiao Y; Peperzak V; Naik SH; Borst J Blood; 2009 May; 113(21):5167-75. PubMed ID: 19279334 [TBL] [Abstract][Full Text] [Related]
3. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy. Shin CA; Cho HW; Shin AR; Sohn HJ; Cho HI; Kim TG Oncotarget; 2016 Jul; 7(29):46173-46186. PubMed ID: 27323820 [TBL] [Abstract][Full Text] [Related]
4. A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells. Oba T; Hoki T; Yamauchi T; Keler T; Marsh HC; Cao X; Ito F J Immunol; 2020 Oct; 205(7):1867-1877. PubMed ID: 32848036 [TBL] [Abstract][Full Text] [Related]
5. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
6. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cho HI; Celis E Cancer Res; 2009 Dec; 69(23):9012-9. PubMed ID: 19903852 [TBL] [Abstract][Full Text] [Related]
7. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491 [TBL] [Abstract][Full Text] [Related]
8. Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responses. Kurche JS; Burchill MA; Sanchez PJ; Haluszczak C; Kedl RM J Immunol; 2010 Aug; 185(4):2106-15. PubMed ID: 20639485 [TBL] [Abstract][Full Text] [Related]
9. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440 [TBL] [Abstract][Full Text] [Related]
10. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects. Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817 [TBL] [Abstract][Full Text] [Related]
11. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling. Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534 [TBL] [Abstract][Full Text] [Related]
12. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model. Powell KL; Stephens AS; Ralph SJ Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808 [TBL] [Abstract][Full Text] [Related]
13. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656 [TBL] [Abstract][Full Text] [Related]
14. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714 [TBL] [Abstract][Full Text] [Related]
15. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. Hao S; Yuan J; Xiang J J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150 [TBL] [Abstract][Full Text] [Related]
17. An optimized peptide vaccine strategy capable of inducing multivalent CD8 Cho HI; Jung SH; Sohn HJ; Celis E; Kim TG Oncoimmunology; 2015 Nov; 4(11):e1043504. PubMed ID: 26451316 [TBL] [Abstract][Full Text] [Related]
18. Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. Bak SP; Barnkob MS; Bai A; Higham EM; Wittrup KD; Chen J J Immunol; 2012 Aug; 189(4):1708-16. PubMed ID: 22798683 [TBL] [Abstract][Full Text] [Related]
19. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913 [TBL] [Abstract][Full Text] [Related]
20. CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice. Bathke B; Pätzold J; Kassub R; Giessel R; Lämmermann K; Hinterberger M; Brinkmann K; Chaplin P; Suter M; Hochrein H; Lauterbach H Immunology; 2018 Jun; 154(2):285-297. PubMed ID: 29281850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]